GENEVA — The World Health Organization has issued a global alert regarding three contaminated cough syrups produced in India, marking yet another instance of dangerous quality-control lapses that have resulted in the deaths of at least 22 children. The affected products, known as Coldrif, Respifresh TR, and ReLife, were manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma.
The tainted syrups contain diethylene glycol, a toxic substance that has previously been linked to several health crises involving Indian-made medications. Reports indicate that these syrups are typically used for treating common ailments such as coughs and colds. The situation has raised red flags for health authorities worldwide as concerns mount over the safety of pharmaceuticals produced in the region.
India’s Central Drugs Standard Control Organization confirmed the presence of the toxic compound in specific batches of these cough syrups. While the Indian health regulator indicated that these contaminated medications have not been exported and that there is no evidence of illegal cross-border trade, the WHO has called on public health officials globally to enhance surveillance efforts and report any sightings of these products.
In recent years, India has gained a reputation as a leading supplier of inexpensive, generic medications. However, maintaining consistent manufacturing standards across its numerous smaller pharmaceutical companies has proved challenging. This incident follows a tragic event in 2022 when over 60 children in Gambia died after consuming a contaminated cough syrup manufactured in India.
The WHO has urged public health authorities to focus on unregulated supply chains where these cough syrups might still be circulating undetected. Furthermore, it has recommended that any oral medications produced at the implicated facilities since December be scrutinized closely.
In response to the public health threat, Indian authorities have launched a criminal investigation into the manufacturers involved. According to the Ministry of Health and Family Welfare, the Tamil Nadu state government has already revoked the license of Sresan Pharmaceutical, and production has been halted.
Regional bodies have been instructed to implement stricter testing protocols for both raw ingredients and finished products to ensure safety before they reach consumers. The Indian drug regulator announced a recall of the tainted cough syrups and is working with state governments to enforce immediate bans on the implicated medications.
As the investigation unfolds, the WHO remains committed to collaborating with Indian health authorities to identify the contamination source and mitigate any further risks to public health. The situation underscores the ongoing challenges that regulatory bodies face in ensuring pharmaceutical safety in a rapidly growing industry.